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ceived preventive treatment; 60.4% were on-demand treatment. Severe HB adults
reported significantly poorer HRQOL than the moderate subgroup mainly on phys-
ical components. No HRQOL difference was observed among children. The average
annual direct cost was €95,619 (SD 83,142) with no significant difference between
adults and children, but with a difference with severity status (3.3 times higher in
severe vs. moderate HB, p0.001). Substitutive therapy represented 90%, of the
total followed by hospitalizations 6.5%. Even if the prophylaxis strategy lead to
higher costs than an on-demand strategy (p0.001), it allows avoiding haemor-
rhagic events and remains in acceptable cost-effectiveness range. CONCLUSIONS:
To date, no economic burden of disease studies focusing only on HB have been
published. The EQOFIX study provides an important source of economic informa-
tion for health care payers.
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OBJECTIVES: The purpose of this study was to characterise the subjective experi-
ence of anaemic patients with CKD and specifically to identify a set of the most
salient symptoms and impacts associated with anaemia and iron supplementa-
tion, both in pre-dialysis and dialysis patients. METHODS: This was a cross-sec-
tional, semi-qualitative study in which one-on-one concept elicitation interviews
were conducted among CKD subjects treated with iron supplementation, alone or
in conjunction with erythropoiesis-stimulating agents (ESAs). The interviews were
audiotaped and transcribed for thematic content analysis. RESULTS: A total of 40
participants were included with median age 53 (range: 27-83 years) and 55% male.
Twenty-two of the participants were on dialysis and of those nearly all received
intravenous iron (91%) and ESAs (91%). Conversely, the majority of pre-dialysis
patients instead used oral iron (72%) while ESA use was less common (44%) in this
segment. Fatigue was the most frequently reported symptom related to anaemia
(83%). Other common symptoms included shortness of breath and itchiness. The
defining symptoms related to iron supplementation were gastrointestinal in na-
ture (abdominal pain, constipation, flatulence, bloating, nausea and vomiting).
These symptoms negatively affected mood and social activities (28%). A difference
between oral and intravenous iron was that the degree of bothersomeness from
nausea and gastrointestinal side effects was more pronounced in those receiving
iron tablets. Iron supplementation was specifically mentioned by some patients to
cause nausea and vomiting and thus interfering with keeping medication down. As
a result, iron supplementation side effects were severe enough to negatively affect
medication compliance. CONCLUSIONS: The results from this study highlight the
great burden anaemia of CKD can have on quality of life, social life and emotional
well-being. Alternative treatments that avoid the side effects of iron supplemen-
tation have the potential to substantially improve quality of life in this patient
population.
PSY42
EFFECTIVENESS AND SAFETY OF ANTI-TNF AGENTS IN TREATMENT OF
MODERATE TO SEVERE PSORIASIS VULGARIS: RESULTS OF WORK
PRODUCTIVITY AND DAILY ACTIVITY IMPAIRMENT
Koc E1, Ozarmagan G2, Alper S3, Ozgoztasi O4, Tekin NS5, Balci DD6, Onsun N7, Tuzun Y8,
Atakan N9, Ozturkcan S10, Kokturk A11
1Gulhane Military Medical School, Ankara, Turkey, 2Istanbul University Istanbul School of
Medicine, Istanbul, Turkey, 3Ege University Faculty of Medicine, Izmir, Turkey, 4Gaziantep
University Faculty of Medicine, Gaziantep, Turkey, 5Zonguldak Karaelmas University Faculty of
Medicine, Zonguldak, Turkey, 6Mustafa Kemal University Faculty of Medicine, Hatay, Turkey,
7Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey, 8Istanbul University
Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 9Hacettepe University Faculty of Medicine,
Ankara, Turkey, 10Celal Bayar University Faculty of Medicine, Manisa, Turkey, 11Mersin
University Faculty of Medicine, Mersin, Turkey
OBJECTIVES:An observational study to investigate effectiveness and safety of anti-
TNF agents in treatment of moderate-to-severe psoriasis vulgaris was conducted in
25 centres from Turkey. This sub-analysis aimed to evaluate the results of work
productivity and activity impairment. METHODS: Patients (18 years) were fol-
lowed-up 24 weeks (visits at 4, 8, 16 and 24 week after baseline) and psoriasis area
and severity index (PASI), dermatology life quality index (DLQI) and work produc-
tivity and activity impairment (WPAI) questionnaires were completed. RESULTS:A
total of 86 patients (38.4% females, mean(standard deviation) age 42.8(13.5) years,
mean(SD) body mass index 29.5(16.2) kg/m2) with psoriasis vulgaris for mean(SD)
16.4 (8.7) years were included to the study. Of patients; 18.6%, 17.4% and 17.4% were
dyslipidemic, hypertensive and hyperglycaemic, respectively. Unemployment rate
among patients was 59% at baseline. The employed patients reported a median
(interquartile-range) 11(44)% absenteeism rate, 50(40)% presenteeism rate and
57(57)% work productivity loss at baseline and those decreased to median(IQR)
0(0)%, 0(20)% and 0(20)% at week 24, respectively (P0.001, P0.001 and P0.001,
respectively). Among all patients, median(IQR) activity impairment rate decreased
to 5(30)% at week 24 from 60(50)% at baseline (P0.001). Baseline median(IQR) PASI
score was 20(15) and decreased to 2(4) at week 24, whereas baseline median(IQR)
DLQI score was 16(10) and decreased to 1.5(7) at week 24 (P for both 0.001). The
reduction in PASI showed a moderate positive linear correlation with absenteeism,
presenteeism, work productivity and loss activity impairment rate (Rhos 0.47,
0.48, 0.45, 0.49, respectively, for all P0.05). CONCLUSIONS: Moderate-to-severe
psoriasis vulgaris seemed to cause high absenteeism, presenteeism, work produc-
tivity and loss activity impairment rates and anti-TNF agents significantly im-
proved work productivity and activity impairment. Anti-TNF agents also signifi-
cantly reduced PASI and DLQI scores and reduction in PASI was moderately
correlated with work productivity and activity impairment.
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OBJECTIVES: To describe pain medication use in patients with chronic lower back
pain (CLBP) after initiating duloxetine or standard of care (SOC) for pain
management. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult patients with CLBP who initiated duloxetine or SOC (muscle
relaxants, gabapentin, pregabalin, venlafaxine, and tricyclic antidepressants) be-
tween 11/2010 and 4/2011. Treatment initiation was defined as no pill coverage for
duloxetine or SOC in previous 90 day. Included patients had no opioid use in 90
days before initiation. Propensity score matching was used to select patients with
similar baseline demographic and clinical characteristics for duloxetine and SOC
cohorts. Compliance to index medication was assessed via medication possession
ratio (MPR) and proportion of days covered (PDC) for 6 months after initiation.
Proportion receiving opioids and days on opioids after index date were assessed
and regression models were estimated to compare opioid use between cohorts.
RESULTS: 766 patients initiated duloxetine and 6,206 patients initiated SOC. After
matching, 743 patients were selected for the duloxetine (mean age: 57 years; fe-
male: 74%) and SOC (mean age: 57 years; female: 75%) cohorts, respectively. 92% of
duloxetine cohort started on or below recommended daily dose (60mg). Dulox-
etine cohort had significantly higher MPR (0.78 vs. 0.60) and PDC (0.50 vs. 0.31), were
less likely to use opioids (45% vs. 61%), and had fewer days on opioids (mean: 18 vs.
25) than SOC cohort (all p0.001). After adjusting for demographic and clinical
characteristics, duloxetine cohort initiated opioids later than SOC cohort (hazard
ratio: 0.76, 95% confidence interval: 0.65-0.88), and had fewer days on opioids (-6.9,
p0.001). CONCLUSIONS: CLBP patients initiating duloxetine had better compli-
ance to initiated medication and were less likely to use opioids than those initiating
SOC.
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OBJECTIVES: To evaluate the cost effectiveness of azacitidine treatment in com-
parison with Conventional Care Regimens (CCR), available in Greece. The analysis
is based on a National Health Service perspective.METHODS:A Markov model was
explored based on the Phase III randomized trial AZA-001, where patients were
analyzed over their lifetime. The health outcomes were estimated on:i) life years
(LY) gained and ii) Quality Adjusted Life Years (QALYs) gained. The cost outcomes
were the average direct costs associated with each MDS treatment arm (relating to
drugs and medications, monitoring, routine follow-up and adverse event manage-
ment). The cost effectiveness of azacitidine treatment, compared to BSC, LDC, and
SDC treatments, was based on the Incremental Cost Effectiveness Ratio (ICER). The
model was customized into the Greek Health Care Setting by launching a struc-
tured questionnaire addressed to Greek hematologists from 6 Hospitals. They pro-
vide information on the resource use for the management of blood product trans-
fusions and adverse events complications in Greece. RESULTS: The incremental
cost of treating the patients with azacitidine, compared to treating them with BSC
was €94,585. The incremental life years gained for azacitidine compared to BSC
were 2.63. The resulting incremental cost effectiveness ratio (cost per life year
gained) was €35,909 when comparing azacitidine with BSC. Equivalently, the ICER
of treating patients with azacitidine as compared with treating them with LDC or
SDC was €29,708 and €27,074 respectively. With regard to QALYs azacitidine is also
effective resulting in an additional 1.65 QALYs gained compared to BSC, 1.8 QALYs
compared to LDC, and 1.81 QALYs compared to SDC. .The corresponding ICERs
were €57,158, €47,791and €47,651 versus, BCD, LDC and SDC, respectively.
CONCLUSIONS: Azacitidine is a cost effective option for the treatment of Greek
MDS patients generating significant improvements in quality-adjusted survival.
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OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model
capable of quantifying the socio-economic burden and Health-Related Quality of
Life (HRQOL) for patients with rare diseases (RD) and their caregivers in Europe.
Preliminary results from Spain are presented here. METHODS: On-line survey of
patients and carers afected by Cystic Fibrosis, Prader-Willi Syndrome, Haemo-
philia, Duchenne Muscular Dystrophy, Epidermolysis Bullosa, Fragile X Syndrome,
Sclerodermia, Mucopolysaccharidosis, Juvenile Idiopathic Arthritis or Histiocytosis
was launched in Spain through national patients organizations in September 2011
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and it concluded in April 2012. Socioeconomic costs per patient were calculated.
Costs were divided in 4 categories: direct health care costs (drugs, medical visits,
exams, material), direct non-health care formal costs (professional carers, social
services), direct non-health care informal costs (unpaid carers) and indirect costs
(patient’s and carer’s productivity loss). Both patients and their carers completed a
generic scale EQ-5D to measure HRQOL. RESULTS: A total of 697 patients and their
carers responded the questionnaire, 28% affected by Cystic Fibrosis, 21% by Sclero-
derma and 11% by X-Fragile Syndrome. For most of the diseases an important part
of the total costs were the direct non-health care informal costs, i.e. time of pa-
tient’s main carer and other unpaid carers. Total annual cost per patient oscillated
between 20.000 € (Haemophilia) and 200.000 € (Mucopolysaccharidosis). Regarding
the HRQOL measured by EQ-5D, the most affected patients were those with Muco-
polysaccharidosis and Duchenne Muscular Distrophy, which correlated with the
HRQOL of their carers and total costs. CONCLUSIONS: Besides results on costs and
HRQOL presented, the main outcome of BURQOL-RD is an integrated and harmo-
nized set of instruments to assess and monitor socio-economic burden and HRQOL
of patients affected by rare diseases and their carers. The tools developed by
BURQOL-RD will also improve RD awareness and literacy among European citizens.
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OBJECTIVES: To explore the impact of neuropathic pain component on quality of
life in patients with severe, chronic low back pain. METHODS: A phase 3b study
was performed, including a total of 208 patients with severe, chronic low back pain
who had been inadequately managed with World Health Organization Step I or II
analgesics or had no regular analgesic treatment and were switched to tapentadol
prolonged release. The likelihood of a neuropathic pain component (NPC) was
determined using the painDETECT questionnaire: negative (score 0-12), unclear
(score 13-18), or positive (score 19-38). The painDETECT questionnaire was previ-
ously shown to have high sensitivity, specificity and positive predictive accuracy.
RESULTS: Mean pain intensity at baseline, measured with 11-point numerical rat-
ing scale, was slightly higher in patients with painDETECT positive score (7.6) than
in patients with painDETECT unclear (7.3) and patients with painDETECT negative
(7.1) score. However, patients with painDETECT positive score had the mean EQ-5D
value substantially lower (0.31) than patients with pure nociceptive pain (0.44).
Similarly, lower scores were detected in all dimensions of the SF-36 when NPC was
present, especially in social functioning, role-physical, role-emotional, and mental
health. Scores with the Hospital Anxiety and Depression Scale were worse for both
dimensions if NPC was present. Whereas 12% of patients with pure nociceptive
pain rated their overall quality of sleep as poor, there were 27% in patients with
painDETECT positive subset. Moreover, in pre-study period, patients in the pain-
DETECT positive subset consulted a doctor earlier and more frequently, visited
more doctors because of their pain, changed more analgesic regimens since pain
started, and were more absent from work than patients in the painDETECT nega-
tive subset. CONCLUSIONS: The presence of a neuropathic pain component ap-
pears to have a substantial detrimental impact on quality of life in patients with
severe, chronic low back pain.
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OBJECTIVES: Achieving market access requires substantiating incremental value
for the indicated patient population. The aim of this project was to provide an
example of how mapping the relationship between clinical states and health util-
ities can inform early development strategy and clinical trial inclusion criteria.
METHODS: US 2011 National Health and Wellness Survey data were used. Respon-
dents with pain in the past month were included. General linear models were used
to examine the relationship between pain level in the last week (0 to 10 scale) and
health utilities (using the SF6D algorithm) while controlling for sociodemographics
and health history. Models were replicated within pain subgroups (e.g., neuro-
pathic pain, nocioceptive pain etc).RESULTS:A total of 24,778 respondents (33.04%)
reported pain in the past month (mean age 50.24; 51.71% were female). The range
of health utilities was 0.35-1.00. Pain level was significantly associated with health
utilities (b-0.025, p.05), though a cubic relationship was also identified whereby
a 1-point reduction in pain was associated with a greater increase in utilities
among those with mild pain (e.g., a reduction from 1 to 0 on the pain scale led to
0.027 increase in utilities) compared with those with severe pain (reduction from 10
to 9 lead to 0.010 increase in utilities). Subgroups were also investigated; for exam-
ple, only a significant linear relationship (no higher order trends) between pain
level and health utilities was observed among those with neuropathic pain (b-
0.27, p.05). CONCLUSIONS: The overall relationship between the level of pain and
health utilities was non-linear suggesting that more incremental value could be substan-
tiated by reducing milder pain than more severe pain. However, not all subgroups fol-
lowed this pattern emphasizing the benefits of understanding the relationship between
estimated treatment effects and health utilities early in the developmental process to
inform clinical trial design, optimize incremental value, and drive cost effectiveness.
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OBJECTIVES: In January 2012, the protease inhibitors boceprevir and telaprevir
were found to be cost effective in the Irish setting. The complexity of the treatment
regimens, the high cost of the agents and the potential for increased patient mor-
bidity prompted interested clinical specialist groups and health care service pro-
viders to collaborate in the establishment of an outcomes registry for Hepatitis C
patients. The goal of the network was to optimise the quality of care of patients
with hepatitis C (HCV) treated with directly acting antiviral therapy (DAA). The aim
is to describe the process of development of a national outcomes treatment registry
under the auspices of the Irish Hepatitis C Outcomes Registry Network (ICORN).
METHODS: The review took into account the challenges and considerations for the
design, development and implementation of the registry. Identified issues in the
development phase included governance, stakeholder involvement, feasibility,
funding, analysis and ethics and privacy. Those identified in the design phase
included the study design, outcomes and research questions. The implementation
phase will involve training and education, data capture, database management,
monitoring, reporting systems and research. RESULTS: The Executive Committee
was established in the first instance, with the subsequent appointment of a clinical
advisory group sub-committee to develop clinical guidelines and treatment proto-
cols. The outcomes required of the registry were ratified. Seven centres of excel-
lence were identified for data collection. A data capture tool was designed in col-
laboration with software expertise. Data protection considerations were put in
place. A clear reporting structure for funding for the registry was established.
CONCLUSIONS:Observational data generated through the registry allows real time
monitoring of safety, effectiveness and cost effectiveness of triple therapy regimes
in HCV. This project is a reference case in Ireland for extension of health technol-
ogy assessment beyond the reimbursement decision.
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OBJECTIVES: To describe treatment changes following the initiation of a non-bio-
logic DMARD in PsA patients. METHODS: Adult patients with  2 PsA diagnoses
(from office visits) with continuous insurance coverage  6-month before and 
12-month post-index date (i.e., first prescription of a non-biologic DMARD) were
selected from the MarketScan Commercial Claims database (2005-2009). Patients
who used a biologic/non-biologic DMARDs or had a diagnosis of ankylosing spon-
dylitis before the index date were excluded. Treatment discontinuation was de-
fined as a treatment interruption 60 consecutive days. Therapy modification was
defined as a switch (initiation of a biologic/non-biologic DMARD [not used at the
index date] within 60 days of the index biologic discontinuation date) or a therapy
augmentation (use of a non-biologic/biologic DMARD [not used at the index date]
concomitantly with the index non-biologic DMARD for 28 consecutive days). The
12-month therapy modification, switch, and augmentation rates were reported.
RESULTS: A total of 1,698 PsA patients met the selection criteria; 71.7% initiated on
methotrexate, 17.5% on sulfasalazine. Over the 12-month study period, 72.5% of the
patients had 1 therapy change (median time: 86 days). More specifically, 57.7% of
patients discontinued the index non-biologic DMARD, 13.1% switched to a biologic
DMARD, 9.3% switched to another non-biologic DMARD, 21.4% had a therapy augmen-
tation with a biologic DMARD and 7.4% had a therapy augmentation with another
non-biologic DMARD. Among patients who initiated a biologic during the study period
(N513), 90.8% did not use other oral DMARDs, while 9.2% also initiated a second oral
DMARD either in combination or sequentially. CONCLUSIONS: This study suggests
that PsA patients newly initiated on a non-biologic DMARD do not remain on the index
therapy for a long period of time. Most patients switched to or added on biologics
quickly without using a second oral DMARD.
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THE EFFECT OF POSITIONING AND PNF-EXERCISE TO POSTOPERATIVE
BLEEDING AFTER HIP REPLACEMENT
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OBJECTIVES: Postoperative positioning has beneficial effects on postoperative
blood-saving, HGB and HTC reduction after knee replacement, and reduces the
complications of transfusion. METHODS: Total of 96 people with hip replacement
(age 6920) were included in 4 groups who were treated on Orthopaedic Depart-
ment in Zala County Hospital in 2012. I.a.group: traditional way of physiotherapy
following the hospital protocol (not upraised lower limb) I.b.group: the same to I.a.,
supplemented with one special exercise from PNF-method (irradiation, effecting
the operated side; repeat it 5-15 times/hour during the first 3 day) II.a.group: placed
the lower limb in 30° hip and knee flexion  traditional physiotherapy, II.b.group:
same to II.a, supplemented with the special PNF exercise. The postoperative blood
volume (after 6, 24, 48, 72 hours) and HGB, HTC (pre- and postop.24h) were mea-
sured. Data were analysed by Wilcoxon-tests applying SPSS statistic software.
RESULTS: The 30°hip and knee flexion increased the postoperative bleeding
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